- Home
- Who We Are
About Us
Qu Biologics has attracted a team of life sciences professionals who are leaders in their respective fields.
- What We Do
What We Do
Qu Biologics’ SSIs restore innate immune function and reverse the chronic inflammation underlying many conditions such as cancer and immune-related disease.
- Clinical Trials
Clinical Trials
Investigational treatment QBECO SSI is an immunotherapy aimed at restoring normal immune function to reverse the chronic inflammation underlying Crohn’s disease.
- Partner With Us
Partner With Us
To gain a better understanding of the root causes of disease and the potential benefits of novel immunotherapies, Qu Biologics has a number of university research collaborations.
- Qu In The News
- Careers
Careers
Join a team of innovators who have a passion to make a difference. In a short time, our ambitious team has achieved a number of major milestones and we have many big goals ahead.
- Contact Us
News
Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease
Vancouver, British Columbia – July 23rd, 2019 – Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of microbial-based immunotherapies designed to restore the body’s innate immune system, is pleased to report that the results of their first randomized-placebo controlled trial (RCT) in patients with moderate-to-severe Crohn’s disease (CD) […]
READ MORE >Qu Biologics enrolls the first patient in new Phase 2 Crohn’s disease clinical trial
Vancouver, British Columbia – July 25, 2018 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that the first patient in the RESTORE Phase 2 clinical trial for patients with moderate to severe Crohn’s disease has been […]
READ MORE >Crohn’s disease clinical trial – Now enrolling
Qu Biologics is now recruiting Canadian residents to participate in the first stage of a Phase 2 clinical trial of QBECO SSI in the treatment of adults living with moderate to severe Crohn’s disease. The aim of this trial is to further establish the safety and efficacy of the investigational drug QBECO SSI for the […]
READ MORE >Leading-edge Scientists in Innate Immunity Join Qu Biologics’ Scientific Advisory Board
Vancouver, British Columbia – May 15th, 2018 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce the addition of four members to Qu’s Scientific Advisory Board (SAB), consisting of world leading experts in the fields of innate […]
READ MORE >Qu Biologics SSIs featured in Inside Tract magazine
Qu Biologics’ paradigm shifting approach to IBD is featured in the March April 2018 issue of the Gastrointestinal Society’s ‘Inside Tract’ magazine. Read the full article here
READ MORE >Qu Biologics begins Phase 2 Clinical Trial in Crohn’s disease
Qu Biologics Inc. (Qu), a Vancouver, Canada-based biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore innate immune function, is pleased to announce the receipt of a ‘No Objection Letter’ (NOL) from Health Canada and the initiation of their follow-on Phase 2 clinical trial to study QBECO SSI for […]
READ MORE >Julia Levy – a trailblazer for women in STEM
A woman of wisdom and influence and we’re proud to be associated – Julia Levy is a member of Qu Biologics Board of Directors and has blazed a trail for women in STEM. Read more about her journey here .
READ MORE >Protected: IBD Advisory Panel meeting March 6 2018
There is no excerpt because this is a protected post.
READ MORE >Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress
Vancouver, British Columbia – Dec 19th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system is pleased to report that they will be presenting clinical outcome data from Qu’s recently completed Phase 2 study in ulcerative colitis at […]
READ MORE >Discovery of Innate Immune Mechanisms of a Novel Microbial-based Approach for the Treatment of Lung Cancer
Vancouver, British Columbia – November 28th, 2017 – Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has just published collaborative research with Dartmouth College detailing the mechanism of action and efficacy of Qu’s lung-targeted SSI, QBKPN, for the […]
READ MORE >